Corpus overview


MeSH Disease

Human Phenotype

Fever (3)

Chills (1)

Pain (1)

Cough (1)


    displaying 1 - 10 records in total 16
    records per page

    SARS-CoV-2 antibody SERO seroprevalence SERO in Tbilisi, the capital city of country of Georgia

    Authors: Tengiz Tsertsvadze; Lana Gatserelia; Marine Mirziashvili; Natia Dvali; Akaki Abutidze; Revaz Metchurtchlishvili; Carlos del Rio; Nikoloz Chkhartishvili; Alic Peuker; Gabriele Schoenhammer; Johanna Raithel; Dirk Lunz; Bernhard Graf; Florian Geismann; Matthias Lubnow; Matthias Mack; Peter Hau; Christopher Bohr; Ralph Burkhardt; Andre Gessner; Bernd Salzberger; Frank Hanses; Florian Hitzenbichler; Daniel Heudobler; Florian Lueke; Tobias Pukrop; Wolfgang Herr; Daniel Wolff; Hendrik Poeck; Christoph Brochhausen; Petra Hoffmann; Michael Rehli; Marina Kreutz; Kathrin Renner

    doi:10.1101/2020.09.18.20195024 Date: 2020-09-18 Source: medRxiv

    Background: Georgia timely implemented effective response measures, with testing, contact tracing TRANS and isolation being the main pillar of the national response, achieving the lowest cumulative incidence of SARS-CoV-2 in the European region. Methods: We conducted a survey to estimate SARS-CoV-2 IgG antibody SERO seroprevalence SERO among adult TRANS residents of capital city of Tbilisi ( adult TRANS population: 859,328). Participants were recruited through respondent driven sampling during May 18-27, 2020. Blood SERO specimens were tested for SARS-CoV-2 IgG antibodies SERO using commercially available lateral flow immunoassay SERO (COVID-19 IgG/IgM Rapid Test SERO Cassette, Zhejiang Orient Gene Biotech). Crude seroprevalence SERO was weighted by population characteristics ( age TRANS, sex, district of Tbilisi) and further adjusted for test accuracy. Results: Among 1,068 adults TRANS recruited 963 (90.2%) were between 18 and 64 years-old, 682 (63.9%) women. 176 (16.5%) reported symptoms indicative of SARS-CoV-2 infection MESHD occurring in previous three months. Nine persons tested positive for IgG: crude seroprevalence SERO: 0.84%, (95% CI: 0.33%-1.59%), weighted seroprevalence SERO: 0.94% (95% CI: 0.37%-1.95%), weighted and adjusted for test accuracy: 1.02% (95% CI: 0.38%-2.18%). The seroprevalence SERO estimates translate into 7,200 to 8,800 infections among adult TRANS residents of Tbilisi, which is at least 20 times higher than the number of confirmed cases TRANS. Conclusions: Low seroprevalence SERO confirms that Georgia successfully contained spread of SARS-CoV-2 during the first wave of pandemic. Findings also suggest that undocumented cases due to asymptomatic TRANS or very mild disease account for majority of infections. Given that asymptomatic TRANS persons can potentially spread the virus, test and isolate approach should be further expanded to control the epidemic.

    Seroprevalence SERO of SARS-CoV-2 IgG Antibodies SERO in Utsunomiya City, Greater Tokyo, after first pandemic in 2020 (U-CORONA): a household- and population-based study

    Authors: Nobutoshi Nawa; Jin Kuramochi; Shiro Sonoda; Yui Yamaoka; Yoko Nukui; Yasunari Miyazaki; Takeo Fujiwara

    doi:10.1101/2020.07.20.20155945 Date: 2020-07-26 Source: medRxiv

    Background: The number of confirmed cases TRANS of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan are substantially lower in comparison to the US and UK, potentially due to the under-implementation of polymerase chain reaction (PCR) tests. Studies reported that more than half of the SARS-CoV-2 infections are asymptomatic TRANS, confirming the importance for conducting seroepidemiological studies. Although the seroepidemiological studies in Japan observed a reported prevalence SERO of 0.10% in Tokyo, 0.17% in Osaka, and 0.03% in Miyagi, sampling bias was not considered. The study objective was to assess the seroprevalence SERO of SARS-CoV-2 in a random sample of households in Utsunomiya City in Tochigi Prefecture, Greater Tokyo, Japan. Methods: We launched the Utsunomiya COVID-19 seROprevalence SERO Neighborhood Association (U-CORONA) Study to assess the seroprevalence SERO of COVID-19 in Utsunomiya City. The survey was conducted between 14 June 2020 and 5 July 2020, in between the first and second wave of the pandemic. Invitations enclosed with a questionnaire were sent to 2,290 people in 1,000 households randomly selected from Utsunomiya basic resident registry. Written informed consent was obtained from all participants. The level of IgG antibodies SERO to SARS-CoV-2 was assessed by chemiluminescence immunoassay SERO analysis. Results: Among 2,290 candidates, 753 returned the questionnaire and 742 received IgG tests (32.4 % participation rate). Of the 742 participants, 86.8% were 18 years or older, 52.6% were women, 71.1% were residing within 10 km from the test clinic, and 89.2% were living with another person. The age TRANS and sex distribution, distance to clinic and police district were similar with those of non-participants, while the proportion of single-person households was higher among non-participants than participants (16.2% vs. 10.8%). We confirmed three positive cases through quantitative antibody testing SERO. No positive cases were found among the people who live in the same household as someone with positive. All cases were afebrile. The estimated unweighted and weighted prevalence SERO of SARS-CoV-2 infection were 0.40% (95% confidence interval: 0.08-1.18%) and 1.23% (95% confidence interval: 0.17-2.28%), respectively. Conclusion: This study suggests the importance of detecting all cases using PCR or antigen testing, not only at a hospital, but also in areas where people assemble. Further prospective studies using this cohort are needed to monitor SARS-CoV-2 antibody SERO levels.

    SARS-CoV-2 serosurvey in Health Care Workers of the Veneto Region

    Authors: Mario Plebani; Andrea Padoan; Ugo Fedeli; Elena Schievano; Elena Vecchiato; Giuseppe Lippi; Giuliana Lo Cascio; Stefano Porru; Giorgio Palu

    doi:10.1101/2020.07.23.20160457 Date: 2020-07-24 Source: medRxiv

    Background: The ongoing outbreak of coronavirus disease MESHD (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays SERO may improve disease management when appropriately used, for better understanding the antibody SERO responses mounted upon SARS-CoV-2 infection MESHD and for assessing its real prevalence SERO. Although testing the whole population is impratical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. Aim: we evaluated the prevalence SERO of SARS-CoV-2 infection MESHD in health care workers who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region by measuring specific antibodies SERO (Abs). Methods: both IgM and IgG antibodies SERO against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi 2000 Plus (New Industries Biomedical EngineeringCo., Ltd [Snibe], Shenzhen, China) Results: A total of 8285 health care workers were tested. SARS-CoV-2 specific antibodies SERO (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1-5.0%). Seroconversion was observed in 4.4% women and 5% men, but the difference was not significant. Although detectable antibodies SERO were found in all severe COVID-19 patients (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence SERO (58%) was observed in asymptomatic TRANS subjects. Conclusion: Seroprevalence SERO surveys are of utmost importance for understanding the rate of population that has already developed antibodies SERO against SARS-CoV-2. The present study has the statistical power to define precisely the circulation of SARS-CoV-2 in a cohort of health workers in our region, with its prevalence SERO (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody SERO positive, whilst Abs were only detectable in 58% of asymptomatic TRANS carriers TRANS.

    Community-level SARS-CoV-2 Seroprevalence SERO Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research.

    Authors: Silvana Figar; Vanina Pagotto; Lorena Luna; Julieta Salto; Magdalena Wagner Manslau; Alicia Mistchenko; ANDREA GAMARNIK; Ana Maria Gomez Saldano; Fernan Quiros

    doi:10.1101/2020.07.14.20153858 Date: 2020-07-16 Source: medRxiv

    Background By July 1st, the incidence rate of RT-qPCR SARS-CoV-2 infection was 5.9% in Barrio Padre Mugica, one of the largest slums in Buenos Aires City. This study aimed to establish the seroprevalence SERO of SARS-CoV-2 three months after the first case was reported. Methods Between June 10th and July 1st, a cross-sectional design was carried out on people over 14 years old, selected from a probabilistic sample of households. A finger prick sample was tested by ELISA SERO to detect IgG-class antibodies SERO against SARS-CoV-2. Multilevel model was applied to understand sector, household and individual conditions associated with seroconvert. Results Prevalence SERO based on IgG was 53.4% (95%IC 52.8% to 54.1%). Among the IgG positive cases, 15% reported having compatible symptoms at some point in the past two months. There is evidence of within-household clustering effect (rho=0.52; 95% IC 0.36-0.67); living with a PCR- confirmed case TRANS doubled the chance of being SARS-CoV2 IgG positive (OR 2.13; 95% IC 1.17-3.85). The highest risk of infection TRANS risk of infection TRANS infection MESHD was found in one of the most deprived areas of the slum, the Bajo autopista sector. Discussion High seroprevalence SERO is shown, for each symptomatic RT-qPCR-confirmed diagnosis, 9 people were IgG positive, indicating a high rate of undetected (probable asymptomatic TRANS) infections. Given that transmission TRANS among family members TRANS is a leading driver of the disease`s spread, it is unsurprising that crowded housing situations in slums are directly associated with higher risk of infection TRANS risk of infection TRANS infection MESHD and consequently high seroprevalence SERO levels. This study contributes to the understanding of population immunity against SARS-CoV2, its relation to living conditions and viral spread, for future decision making.

    Antibody SERO dynamics to SARS-CoV-2 in Asymptomatic TRANS and Mild COVID-19 patients

    Authors: Qing Lei; Yang Li; Hongyan Hou; Feng Wang; Yandi Zhang; Danyun Lai; Banga Ndzouboukou Jo-Lewis; Zhaowei Xu; Bo Zhang; Hong Chen; Zhuqing Ouyang; Junbiao Xue; Xiaosong Lin; Yunxiao Zheng; Zhongjie Yao; Xuening Wang; Caizheng Yu; Jeremy Jiang; Hainan Zhang; Huan Qi; Shujuan Guo; Shenghai Huang; Ziyong Sun; Sheng-ce Tao; Xionglin Fan

    doi:10.1101/2020.07.09.20149633 Date: 2020-07-11 Source: medRxiv

    Abstract Importance Asymptomatic TRANS COVID-19 infections have a long duration of viral shedding and contribute substantially to disease transmission TRANS. However, the missing asymptomatic TRANS cases have been significantly overlooked because of imperfect sensitivity SERO of nucleic acid testing. We aimed to investigate the humoral immunity in asymptomatics TRANS, which will help us develop serological tests SERO and improve early identification, understand the humoral immunity to COVID-19, and provide more rational control strategies for the pandemic. Objective To better control the pandemic of COVID-19, dynamics of IgM and IgG responses to 23 proteins of SARS-CoV-2 and neutralizing antibody SERO in asymptomatic TRANS COVID-19 infections after exposure time were investigated. Design, setting, and participants 63 asymptomatic TRANS individuals were screened by RT-qPCR and ELISA SERO for IgM and IgG from 11,776 personnel returning to work, and close contacts TRANS with the confirmed cases TRANS in different communities of Wuhan by investigation of clusters and tracing TRANS infectious sources. 63 healthy contacts with both negative results for NAT and antibodies SERO were selected as negative controls. 51 mild patients without any preexisting conditions were also screened as controls from 1056 patients during hospitalization in Tongji Hospital. A total of 177 participants were enrolled in this study and serial serum samples SERO (n=213) were collected. The research was conducted between 17 February 2020 and 28 April 2020. Serum SERO IgM and IgG profiles of 177 participants were further probed using a SARS-CoV-2 proteome microarray. Neutralizing antibody SERO responses in different population were detected by a pseudotyped virus neutralization assay system. The dynamics of IgM and IgG antibodies SERO and neutralizing antibodies SERO were analyzed with exposure time or symptoms onset TRANS. Results Asymptomatics TRANS were classified into four subgroups based on NAT and serological tests SERO. In particular, only 19% had positive NAT results while approximately 81% detected positive IgM/IgG responses. Comparative SARS-CoV-2 proteome microarray further demonstrated that there was a significantly difference of antibody SERO dynamics responding to S1 or N proteins among three populations, although IgM and IgG profiles could not be used to differentiate them. S1 specific IgM responses were elicited in asymptomatic TRANS individuals as early to the seventh day after exposure and peaked on days from 17d to 25d, which might be used as an early diagnostic biomarker and give an additional 36.5% seropositivity. Mild patients produced stronger both S1 specific IgM and neutralizing antibody SERO responses than asymptomatic TRANS individuals. Most importantly, S1 specific IgM/IgG responses and the titers of neutralizing antibody SERO in asymptomatic TRANS individuals gradually vanished in two months. Conclusions and relevance Our findings might have important implications for the definition of asymptomatic TRANS COVID-19 infections, diagnosis, serological survey, public health and immunization strategies.

    Estimation of Undetected Symptomatic and Asymptomatic TRANS cases of COVID-19 Infection and prediction of its spread in USA

    Authors: Ashutosh Mahajan; Ravi Solanki; Namitha Sivadas

    doi:10.1101/2020.06.21.20136580 Date: 2020-06-23 Source: medRxiv

    The reported COVID-19 cases in the USA have crossed over 2 million, and a large number of infected cases are undetected whose estimation can be done if country-wide antibody testing SERO is performed. In this work, we estimate this undetected fraction of the population by modeling and simulation approach. We propose a new epidemic model SIPHERD in which three categories of infection MESHD carriers TRANS Symptomatic, Purely Asymptomatic TRANS, and Exposed are considered with different transmission TRANS rates that are taken dependent on the lockdown conditions, and the detection rate of the infected MESHD carriers TRANS is taken dependent on the tests done per day. The model is first validated for Germany and South Korea and then applied for prediction of total number of confirmed, active and death MESHD, and daily new positive cases in the United States. Our study also demonstrates the possibility of a second wave of the infection MESHD if social distancing regulations are relaxed to a large extent. We estimate that around 12.7 million people are already infected, and in the absence of any vaccine, 17.7 million (range: 16.3-19.2) people, or 5.3% (range: 4.9-5.8) of the population will be infected by when the disease spread TRANS ends in the USA. We find the Infection to Fatality Ratio to be 0.93% (range: 0.85-1.01).

    Rapid Screening Diagnosis of SARS-COV-2 Infection MESHD With IgM-igG Combined Antibody Test SERO Using Peripheral Blood SERO

    Authors: Zhengtu Li; Shaoqiang Li; Youwei Wang; Yongkang Liao; Hui Chen; Jing Cheng; Ye Lin; Zhaoming Chen; Kangjun Sun; Min Zhang; Mindie Wang; Xinni Wang; Xinyan Yang; Wensheng Cai; Yangqing Zhan; Shiyue Li; Nanshan Zhong; Feng Ye

    doi:10.21203/ Date: 2020-06-20 Source: ResearchSquare

    Background Rapid and convenient screening for identification of SARS-CoV-2 infected MESHD individuals are key to prevent and control this pandemic.Methods The peripheral blood SERO samples were collected from coronavirus disease MESHD 2019 (COVID-19) patients and asymptomatic TRANS carriers TRANS to evaluate the test characteristics of the IgM-IgG combined assay for SARS-CoV-2 compared to that of serum samples SERO and enzyme-linked immuno sorbent assay (ELISA SERO). Close contacts TRANS, healthcare workers and workforces were recruited and screened using this assay.Results The sensitivity SERO of the rapid IgM-IgG combined antibody test SERO for SARS-CoV-2 using peripheral blood SERO (sued as a POCT) was 97.0% and the specificity was 99.2%, which was consistent with the result obtained using serum sample SERO (consistency is about 100%). Furthermore, this POCT assay also can detect IgM and IgG antibodies SERO of SARS-CoV MESHD‐2 in asymptomatic TRANS carriers TRANS, with 19 of the 20 RT-PCR confirmed asymptomatic TRANS carriers TRANS testing positive. Therefore, this POCT assay was used for population screening of SARS-CoV-2 infection MESHD diagnosis. First, it found 4 positive close contacts TRANS among the 10 cases, and there were three IgM positive cases and one IgG positive case among them. It is worth noting that the IgM positive cases also tested positive for the nucleic acid of the SARS-CoV-2. Second, there was one IgM positive assay among the 63 healthcare workers, but RT-PCR of SARS CoV-2 was negative. Third, for workforces screening, there were no positive cases.Conclusions The IgM-IgG combined antibody test SERO of SARS-CoV-2 can be used as a POCT for rapid screening of SARS-CoV-2 infection MESHD.

    Sensitivity SERO and specifity of prediction models based on gustatory disorders in diagnosing COVID-19 patients: a case-control study.

    Authors: Kamil Adamczyk; Michal Herman; Janusz Fraczek; Robert Piec; Barbara Szykula-Piec; Artur Zaczynski; Rafal Wojtowicz; Krzysztof Bojanowski; Ewa Rusyan; Zbigniew Krol; Waldemar Wierzba; Edward Franek

    doi:10.1101/2020.05.31.20118380 Date: 2020-06-03 Source: medRxiv

    Abstract Objective: to quantitatively assess disturbances of sweet, sour and salty and bitter tastes in a group of young, asymptomatic TRANS or oligosymptomatic COVID-19 patients; establish a reliable, sensitive and specific test that can diagnose COVID-19 on the basis of taste disorders MESHD and publish the results according to STARD 2015 statement (Standards for Reporting Diagnostic Accuracy). Design: case-control study Setting: isolated rooms in the Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw (which had been transformed into an infectious hospital) and a dormitory in one of Warsaw universities. Participants: 52 SARS-CoV-2 positive (51 men, mean age TRANS 21.7 years) and 36 negative students (34 men, mean age TRANS 20.8 years). Main outcome measures: a gustatory function assessment (sweet, salty, sour and bitter taste), with flavour concentrations established previously in healthy subjects was conducted for all subjects. Each participant received one tasteless reference and nine flavour tablets with sucrose concentrations of 40, 80 and 106.4 mg/ml; NaCl at 13.5, 17 and 27 mg/ml; ascorbic acid at 6.25 and 12.5 mg/ml and grapefruit extract at 40 mg/ml. Results: the only taste that was impaired significantly more frequently in COVID-19 patients was the sweet taste at the lowest flavour concentration (40 mg/ml, p = 0.002). Different screening and diagnostic models were constructed using the examined variables. The highest accuracy screening test consisted of the positive result of a three-question questionnaire (self-reported loss of taste, self-reported loss of smell, or fever HP within the last month (positive if at least one present) and/or ageusia of sweet taste at a sucrose concentration of 40 mg/ml. The sensitivity SERO of the model was 94% with a specificity of 55%. The highest accuracy diagnostic test consisted of ageusia of sweet taste at a sucrose concentration of 106.4 mg/ml or/and ageusia of salty taste at an NaCl concentration of 13.5 or 17 mg/ml. The specificity of the test was found to be 100%, and the sensitivity SERO was 34%. Conclusion: as the most effective way of controlling the present pandemic involves testing the wider population for symptomatic, oligosymptomatic and asymptomatic TRANS carriers TRANS of SARS-CoV-2 and isolating or hospitalising infected subjects, in the present study, an inexpensive, simple, fast and sensitive (94%) screening test that can be used for such a purpose is proposed. In addition, a specific (100%) diagnostic test that could be used to refer patients to quarantine in the case of limited availability of genetic or serological tests SERO is proposed.

    Global lessons and Potential strategies in combating COVID-19 pandemic in Ethiopia:Systematic Review

    Authors: Yimam Getaneh; Ajanaw Yizengaw; Sisay Adane; Kidist Zealiyas; Zelalem Abate; Sileshi Leulseged; Hailemichael Desalegn; Getnet Yimer; Ebba Abate

    doi:10.1101/2020.05.23.20111062 Date: 2020-05-26 Source: medRxiv

    Background: Coronavirus disease 2019 (COVID-19) is a rapidly emerging disease MESHD that has been classified a pandemic by the World Health Organization (WHO). In the absence of treatment for this virus, there is an urgent need to find alternative public health strategies to control the spread. Here, we have conducted an online search for all relevant public health interventions for COVID-19. We then characterize and summarize the global COVID-19 pandemic situation and recommend potential mitigation strategies in the context of Ethiopia. Methods: Initial search of Pub Med central and Google scholar was undertaken followed by analysis of the text words; COVID-19,SARS-CoV-2, Global lessons and Pandemic; A second search using all identified keywords including COVID-19, Epidemiology, Sociocultural, Ethiopia; thirdly, the reference list of all identified reports and articles were searched. Accordingly, of the 1,402 articles, 39 were included in the analysis for this review. Result: Countries COVID-19 mitigation strategies widely varied. The most common global COVID-19 mitigation strategies include; whole of government approach including individual, community and environmental measures, detecting and isolating cases, contact tracing TRANS and quarantine, social and physical distancing measures including for mass gatherings and international travel TRANS measures. Models revealed that, social and physical distancing alone could prevent the pandemic from 60-95%, if timely and effectively implemented. Moreover, detecting and isolation of cases were found to be crucial while access to testing was found to the global challenge. Individual measures including proper hand washing were also reported to be effective measures in preventing the pandemic. Asymptomatic TRANS cases of COVID-19 ranged from 25% to 80% and as a result, countries are revising the case definition for early detection of mild symptomatic cases of COVID-19 with inclusion of Chills HP, Muscle pain MESHD pain HP and new loss of taste or smell in addition to Cough HP, Shortness of breath, Fever MESHD Fever HP and Sore throat. Global reports also revealed that the incubation period TRANS of COVID-19 could go to 24 days. Ethiopia is also unique in the aspects of sociocultural prospects while more than 99.3% of the population has a religion. Moreover, 69% of the population is under the age TRANS of 29 years old and the health policy in the country focused on prevention and primary health care. All these could be potential entries and opportunities to combat COVID-19 pandemic in the context of Ethiopia. Conclusion: While recommendations may change depending on the level of outbreak, we conclude that in Most countries have benefited from early interventions and in setups like Africa including Ethiopia where health system capability is limited, community engagement supported by local evidence with strict implementation of social and physical distancing measures is mandatory. Active involvement of religious Institutions and mobilizing youth could be entry to increase public awareness in mitigating COVID-19. Community level case detection could enhance early identification of cases which could be implemented through the health extension program. Isolation and quarantine beyond 14 days could help identify long term carriers TRANS of COVID-19. Validation and use of rapid test SERO kits could be vital to increase access for testing. Revision of case definitions for COVID-19 could be important for early detection and identification of mild symptomatic cases.

    Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 SERO hospitalized patients and asymptomatic TRANS carriers TRANS

    Authors: Etienne Brochot; Baptiste Demey; Antoine Touze; Sandrine Belouzard; Jean Dubuisson; Jean-Luc Schmit; Gilles Duverlie; Catherine Francois; Sandrine Castelain; Francois Helle

    doi:10.1101/2020.05.12.20098236 Date: 2020-05-18 Source: medRxiv

    Objective : The objective of this study was to monitor the anti- SARS-CoV-2 antibody SERO response in infected MESHD patients. Methods : In order to assess the time of seroconversion, we used 151 samples from 30 COVID-19 inpatients and monitored the detection kinetics of anti-S1, anti-S2, anti-RBD and anti-N antibodies SERO with in-house ELISAs SERO. We also monitored the presence of neutralizing antibodies SERO in these samples as well as 25 asymptomatic TRANS carrier TRANS samples using retroviral particles pseudotyped with the spike of the SARS-CoV-2. Results : We observed that specific antibodies SERO were detectable in all inpatients two weeks post- symptom onset TRANS. The detection of the SARS-CoV-2 Nucleocapsid and RBD was more sensitive than the detection of the S1 or S2 subunits. Neutralizing antibodies SERO reached a plateau two weeks post- symptom onset TRANS and then declined in the majority of inpatients. Furthermore, neutralizing antibodies SERO were undetectable in 56% of asymptomatic TRANS carriers TRANS. Conclusions : Our results raise questions concerning the role played by neutralizing antibodies SERO in COVID-19 cure and protection against secondary infection. They also suggest that induction of neutralizing antibodies SERO is not the only strategy to adopt for the development of a vaccine. Finally, they imply that anti- SARS-CoV-2 neutralizing antibodies SERO should be titrated to optimize convalescent plasma SERO therapy.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.